Feike Jeffrey L. 4

What Happened
Jeffrey L. Feike, a director of Tevogen Bio Holdings, was granted 40,000 restricted shares on 2026-07-10. The shares were reported as acquired at $0.00 (no cash exchanged), so the immediate reported value is $0. This is an equity award (compensation), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-10. Grant type: Award/Grant (code A). Reported acquisition price: $0.00. Shares granted: 40,000.
• Shares owned after the transaction: Not disclosed in this filing.
• Footnote: The grant is restricted stock under Tevogen’s 2024 Omnibus Incentive Plan. Vesting occurs in three equal installments tied to both anniversary dates (1st, 2nd, 3rd) and company revenue milestones (aggregate revenue of $50M, $100M, and $150M since the grant date), and requires the reporting person to remain in service on each vesting date.
• Filing timeliness: Report filed on 2026-07-10 (same day as the period of report), indicating a timely disclosure.

Context
This is a standard restricted stock grant used for director compensation. Because vesting depends on revenue targets and continued service, the award may be forfeited if those conditions are not met. Grants at $0 are common for compensation and do not imply an immediate cash value or market sale.